– Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus' strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS) today announced the completion of the previously announced divestiture of its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise through the sale of its subsidiary, Coherus Ophthalmology LLC, to Sandoz, Inc. for upfront all-cash consideration of $170 million. This divestiture in ...

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced that effective February 20, 2024, the compensation committee of the Company's board of directors granted options to purchase an aggregate of 170,000 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $2.59, the closing trading price on the grant date. One Executive Vice President level executive was granted an o ...

– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving UDENYCA® – REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced the launch of UDENYCA ONBODY™, the company's on-body injector (OBI) presentation of UDENYCA® (pegfilgrastim-cbqv), is successfully underway, with a broad distribution of accounts nat ...

Shares of Coherus BioSciences (CHRS 14.85%) climbed 14.9% on Tuesday after the company announced a positive revision to the terms of its loan agreement with Pharmakon Advisors.On the positive fallout of Coherus' recent divestmentIn a press release late yesterday, Coherus announced it has entered into an agreement with Pharmakon Advisors to revise the terms of its loan agreement entered in January 2022. After Coherus closes the previously announced divestiture of its noncore ophthalmology business to Sandoz ...

Shares of Coherus BioSciences (CHRS -7.36%) were sinking 8.6% lower as of 11:14 a.m. ET on Tuesday. The decline followed a nice pop for the stock on Monday after Coherus announced it was selling its Cimerli ophthalmology franchise to Sandoz Group. This deal with Sandoz will allow Coherus to pocket $170 million in cash. The biotech will also receive additional money for its Cimerli product inventory.Are investors conflicted about Coherus' Sandoz deal?It might seem that investors are conflicted about Coherus' ...

Shares of Coherus (CHRS 5.74%) rallied as much as 21.7% early Monday, then gave up its gains to trade up around 2.4% as of 2:40 p.m. ET. This occurred after the company announced an agreement to divest its ophthalmology franchise.Coherus divests a non-core assetIn a press release this morning, Coherus announced a deal to divest its Cimerli franchise, a biosimilar drug to treat vision impairment and loss, to biosimilars company Sandoz Group (SDZN.Y 2.90%). The latter will pay Coherus $170 million in cash up ...

Coherus BioSciences (NASDAQ:CHRS) stock is taking off on Monday after the biopharmaceutical company announced a $170 million divestment.Coherus BioSciences is selling its CIMERLI ophthalmology franchise to Sandoz (OTCMKTS:SDZNY) for an upfront payment of $170 million. That payment will be made in cash and the sale includes supporting commercial infrastructure for CIMERLI.To go along with this, Coherus BioSciences will also sell all CIMERLI product inventory at a later date for additional funds. The sale is ...

– Transaction aligns to Coherus' strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced it has entered into an agreement to divest its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise, inclusive of CIMERLI and its supporting commercial infrastructure, to Sandoz for upfront, all-cash consideration of $170 million plus an additional amount ...

– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses – – Data support casdozo as a promising novel immuno-oncology agent with clinical activity in liver cancer that may be associated with IL-27 pathway biomarkers – – Data support continued evaluation of casdozo with VEGF and PD-(L)1 blockade in HCC, including further clinical development to evaluate casdozokitug/toripalimab/bevacizumab – REDWOOD CITY, Calif., Jan. 18, ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Conference Call November 6, 2023 5:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Dennis Lanfear - President, CEO and Chairman Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Rosh Dias - Chief Medical Officer McDavid Stilwell - Chief Financial Officer Conference Call Participants Robyn Karnauskas - Truist Securities Yigal Nochomovitz - Citigroup Michael Nedelcovych - TD Cowen Douglas Tsao - ...